araag2/HINT huggingface dataset:
Clinical trial NCT03848182 (phase 2, status: terminated)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically or cytologically confirmed adenocarcinoma of the pancreas

          2. Patients is a candidate for gemcitabine chemotherapy (adjuvant, metastatic, locally
             advanced, borderline resectable settings all permitted)

          3. Patients at least 18 years of age

          4. ECOG performance status 0-2

          5. Consent to donate 12 tubes of peripheral blood of 10 mL each

          6. Adequate organ function as defined as -neutrophil count ≥ 1200 -platelets ≥ 75,000
             -hemoglobin ≥ 8.0 -bilirubin ≤ 2.0 -creatinine ≤2.0 or calculated GFR ≥ 30

          7. Ability to understand and willingness to sign a written informed consent document

          8. Prior chemotherapy permitted, as long as 60 days have lapsed since last dose. Prior
             radiation therapy permitted, as long as 28 days lapsed since last treatment.

          9. Patients may receive other concurrent chemotherapy, immunotherapy, or radiotherapy

        Exclusion Criteria:

          1. Patients never been immunized with tetanus toxoid (TT). Patients with a history of
             adverse reaction to tetanus vaccine (with the exception of self-limited fever or local
             tissue reaction

          2. Patients may not be receiving any investigational agents

          3. Pregnant women

          4. Patients with HIV
Clinical trial NCT03907072 (phase 2/phase 3, status: terminated)
Conditions: duchenne muscular dystrophy
ICD codes: G71.01
Drugs: wve-210201 (suvodirsen), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          1. Diagnosis of DMD based on clinical phenotype with increased serum creatine kinase

          2. Documented mutation in the Dystrophin gene associated with DMD that is amenable to
             exon 51 skipping

          3. Ambulatory male, able to walk independently for at least 10 meters in 10 seconds or
             less at the time of Screening visit (performed as part of the NSAA)

          4. Stable pulmonary and cardiac function, as measured by:

               1. Reproducible percent predicted forced vital capacity (FVC) ≥50%

               2. Left ventricular ejection fraction (LVEF) >55% in patients <10 years of age and
                  >45% in patients ≥10 years of age, as measured (and documented) by echocardiogram

          5. Currently on a stable corticosteroid therapy regimen, defined as initiation of
             systemic corticosteroid therapy occurred ≥6 months prior to Screening, and no changes
             in dosing ≤3 months prior to Screening visit

        Exclusion Criteria:

          1. Cardiac insufficiency:

               1. Severe cardiomyopathy that, in the opinion of the Investigator, prohibits
                  participation in this study; however, cardiomyopathy that is managed by
                  angiotensin-converting-enzyme (ACE) inhibitors or beta blockers is acceptable
                  provided the patient meets the LVEF inclusion criterion

               2. Any other evidence of clinically significant structural or functional heart
                  abnormality

               3. A cardiac troponin I value > 0.2 ng/mL

          2. Need for daytime mechanical or non-invasive ventilation OR anticipated need for
             daytime mechanical or non-invasive ventilation within the next year, in the opinion of
             the Investigator. Nighttime non-invasive ventilation is permitted

          3. Received prior treatment with drisapersen or with an investigational
             peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)

          4. Received prior treatment with gene therapy for DMD

          5. Received treatment with ataluren or eteplirsen within the 14 weeks prior to the
             planned Baseline biopsy collection

          6. Received any investigational drug within 3 months or 5 half-lives, whichever is
             longer, prior to the planned Baseline biopsy collection
Clinical trial NCT04409327 (phase 2, status: terminated)
Conditions: covid19
ICD codes: U07.1, Z86.16, U09.9, Z11.52, Z20.822
Drugs: rtb101, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    insufficient accrual rate
  
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent must be obtained from the subject or health care proxy before any
             assessment is performed.

          -  Adults (male and female) aged 65 years and over.

          -  Residing in a nursing home in which one or more residents or staff has developed
             laboratory-confirmed symptomatic COVID-19 infection at the time of randomization

        Exclusion Criteria:

        Subjects will not be eligible if they meet any of the following criteria:

          -  Any subject who is a current smoker or has a ≥ 10 pack year smoking history.

          -  Subjects with a medical history of chronic obstructive pulmonary disease (COPD).

          -  Subjects who are in hospice or receiving comfort care only.

          -  Subjects who have symptomatic laboratory-confirmed COVID-19 at the time of screening
             or randomization.

          -  Subjects with current evidence of an unstable medical disorder including an unstable
             respiratory disorder, gastrointestinal disorder (including Child-Pugh class B and C
             hepatic impairment), renal disorder (including subjects with an estimated glomerular
             filtration rate (eGFR) ≤30 mL/min/1.73m2), or hematologic disorder (including active
             leukemia).

          -  Subjects receiving immunosuppressive therapy including chronic use of prednisone >10
             mg daily (however, inhaled corticosteroids and acute use of higher doses of prednisone
             to treat conditions such as exacerbation of asthma or other acute conditions are
             allowed).

          -  Subjects with an immunodeficiency disease, including a positive human immunodeficiency
             virus (HIV) test result.

          -  Sexually active males with a partner of child-bearing potential
Clinical trial NCT04439305 (phase 2, status: withdrawn)
Conditions: advanced lymphoma, advanced malignant solid neoplasm, hematopoietic and lymphoid cell neoplasm, refractory lymphoma, refractory malignant solid neoplasm, refractory plasma cell myeloma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, R18.0, C17.3, G21.0, J91.0, C05.2, C10.0, C16.0, C96.20, C96.29, D47.09, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, D46.4, D46.1, D46.A, D46.0, D46.20, D46.21, D46.22, D46.4, D46.1, D46.A, D46.0, D46.20, D46.21, D46.22
Drugs: dasatinib
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Reason stopped: 
    zero accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have met applicable eligibility criteria in the Master MATCH Protocol
             prior to registration to treatment subprotocol

          -  Patients must have one of the following missense mutations in DDR2: S768R, I638F,
             L239R

          -  Patients must have an electrocardiogram (ECG) within 8 weeks prior to treatment
             assignment and must have no clinically important abnormalities in rhythm, conduction
             or morphology of resting ECG (e.g. complete left bundle branch block, third degree
             heart block)

          -  Patients with known left ventricular dysfunction must have an echocardiogram (ECHO) or
             a nuclear study (multigated acquisition scan [MUGA] or First Pass) within 4 weeks
             prior to registration to treatment and must not have left ventricular ejection
             fraction (LVEF) < institutional lower limit of normal (LLN). If the LLN is not defined
             at a site, the LVEF must be > 50% for the patient to be eligible

        Exclusion Criteria:

          -  Patients must not have known hypersensitivity to dasatinib or compounds of similar
             chemical or biologic composition

          -  Patients with prior use of dasatinib will be excluded

          -  Dasatinib should NOT be given in the presence of STRONG CYP 3A4 inhibitors/inducers.
             Patients who take these drugs concurrently are ineligible for treatment with
             dasatinib. These drugs must be discontinued prior to initiation of dasatinib

          -  Dasatinib should NOT be given in the presence of H2-antagonists or proton pump
             inhibitors. Patients who take these drugs concurrently are ineligible for treatment
             with dasatinib. These drugs must be discontinued prior to initiation of dasatinib.
             Antacids taken 2 hours before or after dasatinib administration can be used in place
             of H2-antagonists or proton pump inhibitors if some acid-reducing therapy is needed
Clinical trial NCT01670552 (phase 3, status: completed)
Conditions: acute and chronic inflammation, dyspepsia
ICD codes: K30
Drugs: nimesulide + pantoprazole, naproxen + esomeprazole
SMILES: COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1, COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adults male or female aged ≥ 18 years old;

          -  Comply with all the purposes and procedures of the study by signing and dating the
             Informed Consent.

          -  Acute or chronic osteo-articular injury in need of of anti-inflammatory for a period
             of 14 days.

        Exclusion Criteria:

          -  Pregnant women, or women in childbearing age who are not in use effective
             contraception or intending to become pregnant during the study period

          -  History of peptic ulcer or gastric surgery;

          -  Use of Non-steroidal anti-inflammatory (NSAIDs), aspirin, proton pump inhibitor
             (PPIs), H2 blocker and antacid in the past 7 days;

          -  Contraindication to the use of NSAIDs or PPIs;

          -  Renal or hepatic impairment;
Clinical trial NCT01786824 (phase 3, status: terminated)
Conditions: acute kidney injury, renal insufficiency
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0, N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: hydration strategy using saline, hydration strategy using sodium bicarbonate, l-carnitine
SMILES: NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O, NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O, C[N+](C)(C)C[C@H](O)CC([O-])=O
Reason stopped: 
    patient pathway has become infeasible due to pressure for shorter hospital stays. not enough
    inclusions.
  
Eligibility criteria:

        Inclusion Criteria:

          -  The patient must have given his/her informed and signed consent

          -  The patient must be insured or beneficiary of a health insurance plan

          -  The patient is scheduled for a coronarography

          -  The patient can come back to the hospital on days 2 and 7 after the coronarography for
             follow up

          -  The patient has moderate to severe renal insufficiency (glomerular filtration rate <
             60 ml / min / 1.73 m^2)

          -  The patient has not had any oral antidiabetic treatments, or diuretic treatments,
             within 48 hours preceding the coronarography

          -  Lack of treatment with ACE inhibitors or ARA2 24 hours prior to coronary

        Exclusion Criteria:

          -  The patient is participating in another study

          -  The patient is in an exclusion period determined by another study

          -  The patient is under judicial protection

          -  The patient is under any kind of guardianship

          -  The patient refuses to sign the consent form

          -  It is impossible to correctly inform the patient

          -  The patient is unable to participate in follow-up visits at days 2 and 7 after the
             coronarography

          -  The patient is pregnant or breastfeeding

          -  The patient is taking L-carnitine

          -  The patient has a contra indication for a treatment used in this study

          -  Acute heart failure

          -  Infarction, acute phase

          -  Hemodialysis patient

          -  Myeloma

          -  Epileptic patient treated with Depakine (valproic acid) (carnitine can lower
             epilepsy-related thresholds by speeding up the metabolism of Depakine)
Clinical trial NCT01877668 (phase 3, status: completed)
Conditions: psoriatic arthritis
ICD codes: L40.52
Drugs: tofacitinib 5 mg bid, tofacitinib 10 mg bid, adalimumab, placebo, placebo
SMILES: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females, aged >= 18 years at time of consent.

          -  Have a diagnosis of Psoriatic arthritis (PsA) of >= 6 months

          -  Meet the Classification Criteria of PsA (CASPAR) at time of screening

          -  Must not have been adequately treated with a a traditional non-biologic disease
             modifying anti-rheumatic drug (DMARD).

          -  Concurrent treatment with methotrexate, leflunomide, or sulfasalazine allowed and
             required

          -  Must not have taken a biologic Tumour Necrosis Factor Inhibitor

          -  Must have 3 or more swollen joints AND 3 or more tender joints

          -  Must have active psoriasis skin lesions

        Exclusion Criteria:

          -  Have non-plaque forms of psoriasis, eg erythrodermic, guttate or pustular, with the
             exception of nail psoriasis which is allowed

          -  Pregnant or breast feeding, females of child-bearing potential not using highly
             effective contraception

          -  New York Heart Association Class III and IV congestive heart failure

          -  History of hypersensitivity or infusion reaction to biologic agents

          -  Infection with HIV, hepatitis B virus, hepatitis C virus, or other chronic infection
Clinical trial NCT01905059 (phase 3, status: completed)
Conditions: hiv infection
ICD codes: Z21
Drugs: monopi - boosted lopinavir or boosted darunavir, bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine
SMILES: CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1
Eligibility criteria:

        Inclusion Criteria:

          -  HIV infection on second line treatment in the 2lady trial for at least 48 weeks

          -  VL ≤ 200 copies/ml since at least 6 months

          -  No change in ART in the last 3 months previous to the study

          -  CD4> 100 cells/ml

          -  Signed informed consent

          -  Adherence >90

        Exclusion Criteria:

          -  Previous viral failure (at least 2 consecutive HIV RNA >1000 copies/ml) while
             receiving a PI

          -  Ongoing pregnancy and breast feeding women

          -  HBsAg positive patients

          -  opportunistic infection or any severe or progressive disease ongoing or treated in the
             3 months before screening

          -  Subject who in the investigator's opinion is unable to complete the study

          -  History or symptoms of HIV encephalopathy
Clinical trial NCT01905592 (phase 3, status: active, not recruiting)
Conditions: neoplasms, breast, carcinoma of breast, human epidermal growth factor 2 negative carcinoma of breast, brca1 gene mutation, brca2 gene mutation, ovarian neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: niraparib, physician's choice
SMILES: NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          1. Germline BRCA1 or BRCA2 mutation; patients with unknown BRCA status who meet NCCN BRCA
             screening criteria will be screened for BRCA mutation.

          2. Histologically or cytologically confirmed HER2-negative metastatic or locally advanced
             disease that is not amenable to resection or radiation with curative intent.

          3. Up to 2 prior cytotoxic regimens for advanced or metastatic breast cancer; patients
             with no prior cytotoxic regimens for advanced or metastatic disease will only be
             allowed if they relapsed during or within 12 months of (neo-) adjuvant cytotoxic
             therapy.

          4. Prior therapy should have included a taxane and/or anthracycline (unless
             contraindication to those) in the neoadjuvant, adjuvant, or advanced/metastatic
             setting.

             a. Hormone receptor positive patients must also have hormone resistant disease; either
             relapsed while on adjuvant endocrine treatment, or within one year of completing
             adjuvant endocrine treatment, or progression on at least one line of endocrine
             treatment for advanced cancer.

          5. ECOG performance status 0-2

          6. Adequate bone marrow, kidney and liver function

        Exclusion Criteria:

          1. Patients with platinum resistant cancer

          2. Symptomatic uncontrolled brain metastases

          3. Prior diagnosis of Stage IV ovarian cancer; Stage III ovarian cancer must have a
             5-year disease-free interval; Stage II ovarian cancer must have a 2-year disease-free
             interval

          4. Known hypersensitivity to the components of niraparib

          5. Invasive cancer other than breast cancer within 2 years (except basal or squamous cell
             carcinoma of the skin that has been definitely treated)

          6. Pregnant or breast feeding patients

          7. Immunocompromised patients

          8. Known active Hepatitis B or C

          9. Prior treatment with a PARP inhibitor

         10. Known history of myelodysplastic syndrome (MDS).

         11. known and persistent (>4 weeks) >/= grade 3 toxicity or fatigue from prior cancer
             treatment.
Clinical trial NCT01911364 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: bdp/ff/gb, tiotropium, bdp/ff + tiotropium
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female COPD patients aged ≥ 40 years

          -  Current smokers or ex-smokers

          -  FEV1<50% predicted (FEV1/FVC <0,7)

          -  at least 1 documented exacerbations in the last 12 Mo

        Exclusion Criteria:

          -  Pregnant or lactating women and all women physiologically capable of becoming pregnant

          -  Diagnosis of asthma, history of allergic rhinitis or atopy

          -  Patients treated for exacerbations 1 Mo prior to screening

          -  Patients treated with non-cardioselective β-blockers

          -  Patients treated with long-acting antihistamines

          -  Known respiratory disorders other than COPD

          -  Patients who have clinically significant cardiovascular condition
Clinical trial NCT01917331 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: beclometasone/formoterol/glycopyrrolate, beclometasone/formoterol
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female adults aged ≥ 40 years with a diagnosis of COPD

          -  Current smokers or ex-smokers

          -  A post-bronchodilator FEV1 < 50% of the predicted normal value and a post-
             bronchodilator FEV1/FVC < 0.7

          -  At least one exacerbation in the 12 months preceding the screening visit

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Diagnosis of asthma or history of allergic rhinitis or atopy

          -  Patients treated with non-cardioselective β-blockers in the month preceding the
             screening visit

          -  Patients treated for exacerbations in the 4 weeks prior to screening visit

          -  Patients treated with long-acting antihistamines unless taken at stable regimen at
             least 2 months prior to screening and to be maintained constant during the study or if
             taken as PRN

          -  Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic
             hypoxemia

          -  Known respiratory disorders other than COPD

          -  Patients who have clinically significant cardiovascular condition
Clinical trial NCT01940887 (phase 3, status: terminated)
Conditions: age-related macular degeneration
ICD codes: H35.3130, H35.3230, H35.3110, H35.3120, H35.3131, H35.3132, H35.3190
Drugs: e10030, bevacizumab or aflibercept, e10030 sham injection
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects of either gender aged ≥ 50 years

          -  Active subfoveal choroidal neovascularization (CNV) secondary to AMD

          -  Presence of sub-retinal hyper-reflective material (SD-OCT)

        Exclusion Criteria:

          -  Any prior treatment for AMD in the study eye prior to the Day 1 visit, except oral
             supplements of vitamins and minerals

          -  Any prior intravitreal treatment in the study eye prior to the Day 1 visit, regardless
             of indication (including intravitreal corticosteroids)

          -  Any intraocular surgery or thermal laser within three (3) months of trial entry. Any
             prior thermal laser in the macular region, regardless of indication

          -  Subjects with subfoveal scar or subfoveal atrophy are excluded

          -  Diabetes mellitus